TPTX News and Press, Turning Point Therapeutics Inc. From 09/21/20

SAN DIEGO, Sept. 21, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that President and CEO Athena Countouriotis, M.D., will participate in two ...

SAN DIEGO, Aug. 31, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the formation of a scientific advisory board to help guide the companyȁ...

The Food and Drug Administration (FDA) granted  Turning Point Therapeutics ( TPTX +2.0% ) a third Fast-Track designation to its lead drug candidate, repotrectinib for treatment of patients with advanced solid tumors that have an NTRK gene fusion. More news on: Turning Point Therape...

SAN DIEGO, Aug. 24, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the Food and Drug Administration (FDA) granted a third Fast-Track designatio...

Turning Point reports positive data for tumor drug candidate Turning Point Therapeutics ( TPTX ) reported positive preliminary data from its Phase 2 clinical trial TRIDENT-1. The trial is designed to assess the potential of repotrectinib in treating patients with ALK-, ROS1- or NTRK-3-mu...

Turning Point Therapeutics (NASDAQ: TPTX ) announces positive preliminary results from a Phase 2 clinical trial, TRIDENT-1 , evaluating lead candidate repotrectinib in patients with ALK-, ROS1- or NTRK-3-mutation-positive solid tumors. More news on: Turning Point Therapeutics, Inc., H...

ROS1+ TKI-Naïve Non-Small Cell Lung Cancer Confirmed Objective Response Rate is 86 Percent   ROS1+ TKI-Pretreated Non-Small Cell Lung Cancer with One Prior TKI and Prior Chemotherapy, Confirmed Objective Response Rate is 40 Percent   ROS1+ TKI-Pretre...

Early Interim Data from Registrational Phase 2 TRIDENT-1 Study of Lead Drug Candidate Repotrectinib Anticipated in Third Quarter Four Clinical Studies of Three Drug Candidates Ongoing; Early Interim TPX-0022 Data Anticipated in Fourth Quarter   Cash, Cash Equiv...

SAN DIEGO, July 27, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the appointment of Heather Adams as vice president of Human Resources, effec...

SAN DIEGO, July 13, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the appointment of Andrew Partridge as executive vice president and chief co...